Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown
The best hope of controlling the herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) pandemic is the development of an effective vaccine. However, in spite of several clinical trials, starting as early as 1920s, no vaccine has been proven sufficiently safe and efficient to warrant commercial de...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/187585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554537070624768 |
|---|---|
| author | Aziz Alami Chentoufi Elizabeth Kritzer David M. Yu Anthony B. Nesburn Lbachir BenMohamed |
| author_facet | Aziz Alami Chentoufi Elizabeth Kritzer David M. Yu Anthony B. Nesburn Lbachir BenMohamed |
| author_sort | Aziz Alami Chentoufi |
| collection | DOAJ |
| description | The best hope of controlling the herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) pandemic is the development of an effective vaccine. However, in spite of several clinical trials, starting as early as 1920s, no vaccine has been proven sufficiently safe and efficient to warrant commercial development. In recent years, great strides in cellular and molecular immunology have stimulated creative efforts in controlling herpes infection and disease. However, before moving towards new vaccine strategy, it is necessary to answer two fundamental questions: (i) why past herpes vaccines have failed? (ii) Why the majority of HSV seropositive individuals (i.e., asymptomatic individuals) are naturally “protected” exhibiting few or no recurrent clinical disease, while other HSV seropositive individuals (i.e., symptomatic individuals) have frequent ocular, orofacial, and/or genital herpes clinical episodes? We recently discovered several discrete sets of HSV-1 symptomatic and asymptomatic epitopes recognized by CD4+ and CD8+ T cells from seropositive symptomatic versus asymptomatic individuals. These asymptomatic epitopes will provide a solid foundation for the development of novel herpes epitope-based vaccine strategy. Here we provide a brief overview of past clinical vaccine trials, outline current progress towards developing a new generation “asymptomatic” clinical herpes vaccines, and discuss future mucosal “asymptomatic” prime-boost vaccines that could optimize local protective immunity. |
| format | Article |
| id | doaj-art-f383713097ad4462b9da1a80a081c90f |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-f383713097ad4462b9da1a80a081c90f2025-02-03T05:51:25ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/187585187585Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the UnknownAziz Alami Chentoufi0Elizabeth Kritzer1David M. Yu2Anthony B. Nesburn3Lbachir BenMohamed4Laboratory of Cellular and Molecular Immunology, School of Medicine, University of California, Irvine, Irvine, CA 92697-4375, USALaboratory of Cellular and Molecular Immunology, School of Medicine, University of California, Irvine, Irvine, CA 92697-4375, USALaboratory of Cellular and Molecular Immunology, School of Medicine, University of California, Irvine, Irvine, CA 92697-4375, USALaboratory of Cellular and Molecular Immunology, School of Medicine, University of California, Irvine, Irvine, CA 92697-4375, USALaboratory of Cellular and Molecular Immunology, School of Medicine, University of California, Irvine, Irvine, CA 92697-4375, USAThe best hope of controlling the herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) pandemic is the development of an effective vaccine. However, in spite of several clinical trials, starting as early as 1920s, no vaccine has been proven sufficiently safe and efficient to warrant commercial development. In recent years, great strides in cellular and molecular immunology have stimulated creative efforts in controlling herpes infection and disease. However, before moving towards new vaccine strategy, it is necessary to answer two fundamental questions: (i) why past herpes vaccines have failed? (ii) Why the majority of HSV seropositive individuals (i.e., asymptomatic individuals) are naturally “protected” exhibiting few or no recurrent clinical disease, while other HSV seropositive individuals (i.e., symptomatic individuals) have frequent ocular, orofacial, and/or genital herpes clinical episodes? We recently discovered several discrete sets of HSV-1 symptomatic and asymptomatic epitopes recognized by CD4+ and CD8+ T cells from seropositive symptomatic versus asymptomatic individuals. These asymptomatic epitopes will provide a solid foundation for the development of novel herpes epitope-based vaccine strategy. Here we provide a brief overview of past clinical vaccine trials, outline current progress towards developing a new generation “asymptomatic” clinical herpes vaccines, and discuss future mucosal “asymptomatic” prime-boost vaccines that could optimize local protective immunity.http://dx.doi.org/10.1155/2012/187585 |
| spellingShingle | Aziz Alami Chentoufi Elizabeth Kritzer David M. Yu Anthony B. Nesburn Lbachir BenMohamed Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown Clinical and Developmental Immunology |
| title | Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown |
| title_full | Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown |
| title_fullStr | Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown |
| title_full_unstemmed | Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown |
| title_short | Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown |
| title_sort | towards a rational design of an asymptomatic clinical herpes vaccine the old the new and the unknown |
| url | http://dx.doi.org/10.1155/2012/187585 |
| work_keys_str_mv | AT azizalamichentoufi towardsarationaldesignofanasymptomaticclinicalherpesvaccinetheoldthenewandtheunknown AT elizabethkritzer towardsarationaldesignofanasymptomaticclinicalherpesvaccinetheoldthenewandtheunknown AT davidmyu towardsarationaldesignofanasymptomaticclinicalherpesvaccinetheoldthenewandtheunknown AT anthonybnesburn towardsarationaldesignofanasymptomaticclinicalherpesvaccinetheoldthenewandtheunknown AT lbachirbenmohamed towardsarationaldesignofanasymptomaticclinicalherpesvaccinetheoldthenewandtheunknown |